FOLLOWUS
Efficacy of early treatment on 52 patients with preneoplastic hepatitis B virus-associated hepatocellular carcinoma by compound Phyllanthus Urinaria L.
- Chinese Journal of Integrative Medicine Vol. 20, Issue 4, Pages: 263-271(2014)
- Affiliations：
Department of Liver Disease, Shenzhen Hospital Affiliated to Guangzhou University of Chinese Medicine,Guangdong Province,Shenzhen,China
- Author bio：
- Funds：Supported by the National Natural Science Foundation of China (No. 30371790 and No. 30873245), the National Student Abroad Returned Foundation of China (No. 006LHR11), and the Technology Foundation of Shenzhen, China (No. 200304145)
DOI：10.1007/s11655-013-1320-7
CLC：Published：2014，
Published Online：25 March 2013，
Scan for full text
Tong, Gd., Zhang, X., Zhou, Dq. et al. Efficacy of early treatment on 52 patients with preneoplastic hepatitis B virus-associated hepatocellular carcinoma by compound Phyllanthus Urinaria L.., Chin. J. Integr. Med. 20, 263–271 (2014). https://doi.org/10.1007/s11655-013-1320-7
Guang-dong Tong, Xi Zhang, Da-qiao Zhou, et al. Efficacy of early treatment on 52 patients with preneoplastic hepatitis B virus-associated hepatocellular carcinoma by compound Phyllanthus Urinaria L.. [J]. Chinese Journal of Integrative Medicine 20(4):263-271(2014)
Tong, Gd., Zhang, X., Zhou, Dq. et al. Efficacy of early treatment on 52 patients with preneoplastic hepatitis B virus-associated hepatocellular carcinoma by compound Phyllanthus Urinaria L.., Chin. J. Integr. Med. 20, 263–271 (2014). https://doi.org/10.1007/s11655-013-1320-7 DOI：
Guang-dong Tong, Xi Zhang, Da-qiao Zhou, et al. Efficacy of early treatment on 52 patients with preneoplastic hepatitis B virus-associated hepatocellular carcinoma by compound Phyllanthus Urinaria L.. [J]. Chinese Journal of Integrative Medicine 20(4):263-271(2014) DOI： 10.1007/s11655-013-1320-7.
摘要
To observe the change in the number of antibodies of preneoplastic hepatocellular carcinoma (HCC) using early treatment by Compound Phyllanthus Urinaria L. (CPUL) on patients with preneoplastic hepatitis B virus (HBV)-associated HCC. A total of 102 cirrhosis patients with regenerative or dysplastic nodules whose sera were tested positive for at least one of these six proteins (five up-regulated genes URG4
URG7
URG11
URG12 and URG19
and one down-regulated gene DRG2) were assigned randomly to two groups using continual random codes by SPSS software. Fifty-two patients were in the treatment group and 50 patients were in the control group. CPUL was used in the treatment group for 3 years
while the control group did not receive any treatment. The changes in HBV-DNA level
number of antibodies
and hepatocarcinogenesis occurred were observed. Patients who did not develop HCC were followed up for another 2 years. HBV-DNA levels decreased ⩾2log in 22.2% (10/45) of patients in the treatment group in contrast to only 5.0% (2/40) of patients in the control group (P=0.0228). The number of antibodies that were tested positive in the treatment group (1.08±1.01) was significantly lower compared with the control group (2.11±1.12) after 24 months of drug treatment (P<0.01). Both the positive rates of anti-URG11 (33/52) and anti-URG19 (31/52) were over 60% at baseline in the two groups
and were decreased to 48.1% (25/52) and 46.2% (24/52) respectively at 36 months of drug treatment
while the rates increased to 68.0% (34/50) and 66.0% (33/50) respectively (P=0.0417
P=0.0436) in the control group. The positive rate of anti-DRG2 was increased to 55.8% (29/52) at 36 months of drug treatment
while in the control group was decreased to 36.0% (18/50
P=0.0452). Among the 102 patients who developed HCC
2 were in the treatment group and 9 were in the control group
meaning that a significant difference between the two groups (P=0.0212). In 11 patients who developed HCC
anti-URG11 and anti-URG19 were always positive
while anti-DRG2 was negative. Patients newly developing HCC were 6 (20.0%) in the control group
and only one (2.5%) in the treatment group (P=0.0441) during 2-year follow-up after the end of the treatment. Anti-URG11
anti-URG19 and anti-DRG2 could be used as early markers in the prediction of the therapeutic efficacy of CPUL in treating preneoplastic HCC. CPUL is useful in preventing or delaying the development of HBV-associated cirrhosis to HCC.
Abstract
To observe the change in the number of antibodies of preneoplastic hepatocellular carcinoma (HCC) using early treatment by Compound Phyllanthus Urinaria L. (CPUL) on patients with preneoplastic hepatitis B virus (HBV)-associated HCC. A total of 102 cirrhosis patients with regenerative or dysplastic nodules whose sera were tested positive for at least one of these six proteins (five up-regulated genes URG4
URG7
URG11
URG12 and URG19
and one down-regulated gene DRG2) were assigned randomly to two groups using continual random codes by SPSS software. Fifty-two patients were in the treatment group and 50 patients were in the control group. CPUL was used in the treatment group for 3 years
while the control group did not receive any treatment. The changes in HBV-DNA level
number of antibodies
and hepatocarcinogenesis occurred were observed. Patients who did not develop HCC were followed up for another 2 years. HBV-DNA levels decreased ⩾2log in 22.2% (10/45) of patients in the treatment group in contrast to only 5.0% (2/40) of patients in the control group (P=0.0228). The number of antibodies that were tested positive in the treatment group (1.08±1.01) was significantly lower compared with the control group (2.11±1.12) after 24 months of drug treatment (P<0.01). Both the positive rates of anti-URG11 (33/52) and anti-URG19 (31/52) were over 60% at baseline in the two groups
and were decreased to 48.1% (25/52) and 46.2% (24/52) respectively at 36 months of drug treatment
while the rates increased to 68.0% (34/50) and 66.0% (33/50) respectively (P=0.0417
P=0.0436) in the control group. The positive rate of anti-DRG2 was increased to 55.8% (29/52) at 36 months of drug treatment
while in the control group was decreased to 36.0% (18/50
P=0.0452). Among the 102 patients who developed HCC
2 were in the treatment group and 9 were in the control group
meaning that a significant difference between the two groups (P=0.0212). In 11 patients who developed HCC
anti-URG11 and anti-URG19 were always positive
while anti-DRG2 was negative. Patients newly developing HCC were 6 (20.0%) in the control group
and only one (2.5%) in the treatment group (P=0.0441) during 2-year follow-up after the end of the treatment. Anti-URG11
anti-URG19 and anti-DRG2 could be used as early markers in the prediction of the therapeutic efficacy of CPUL in treating preneoplastic HCC. CPUL is useful in preventing or delaying the development of HBV-associated cirrhosis to HCC.
关键词
carcinomahepatic cellserologic preneoplastic markers of hepatocellular carcinomacompound phyllanthus urinaria L.
Keywords
carcinomahepatic cellserologic preneoplastic markers of hepatocellular carcinomacompound phyllanthus urinaria L.
references
Liu Q, Wu WQ, eds. Hepatocellular carcinoma. Beijing: People’s Medical Publishing House; 2000:221–222.
2011 China Health Statistical Yearbook. Beijing: Ministry of Health of the People’s Republic of China; 2010 (Accessed May 27, 2011 at http://www.moh.gov.cn/publicfiles/business/htmlfiles/mohwsbwstjxxzx/s7967/201105/51862.htm)
Kitao A, Zen Y, Matsui O, Gabata T, Nakanuma Y. Hepatocarcinogenesis: multistep changes of drainage vessels at CT during arterial portography and hepatic arteriography—radiologic-pathologic correlation. Radiology 2009;252:605–614.
Arakawa M, Kage M, Sugihara S, Nakashima T, Suenaga M, Okuda K. Emergence of malignant lesions within an adenomatous hyperplastic nodule in a cirrhotic liver. Observations in five cases. Gastroenterology 1986;91:198–208.
Terada T, Terasaki S, Nakanuma Y. A clinicopathologic study of adenomatous hyperplasia of the liver in 209 consecutive cirrhotic livers examined by autopsy. Cancer 1993;72:1551–1556.
Nakashima O, Sugihara S, Kage M, Kojiro M. Pathomorphologic characteristics of small hepatocellular carcinoma: a special reference to small hepatocellular carcinoma with indistinct margins. Hepatology 1995;22:101–105.
Hussain SM, Zondervan PE, Ijzermans JN, Schalm SW, de Man RA, Krestin GP. Benign versus malignant hepatic nodules: MR imaging findings with pathologic correlation. Radiographics 2002;22:1023–1036,1037–1039.
Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009;50:661–662.
EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol 2009;50:227–242.
Terminology of nodular hepatocellular lesions. International Working Party. Hepatology 1995;22:983–993.
Borzio M, Fargion S, Borzio F, Fracanzani AL, Croce AM, Stroffolini T, et al. Impact of large regenerative, low grade and high grade dysplastic nodules in hepatocellular carcinoma development. J Hepatol 2003;39:208–214.
Tong GD, Zhou DQ, He JS, Xiao CL, Liu XL, Zhou XZ, et al. Preneoplastic markers of hepatitis B virus-associated hepatocellular carcinoma and their significance in clinical settings. Chin J Hepatol (Chin) 2007;15:828–832.
Hann HW, Lee J, Bussard A, Liu C, Jin YR, Guha K, et al. Preneoplastic markers of hepatitis B virus-associated hepatocellular carcinoma. Cancer Res 2004;64:7329–7335.
Mengchao W. Progress in diagnosis and treatment of primary liver cancer. Acta Acad Med Sin 2008;30:363–365.
Llovet JM, Bruix J. Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol 2008;48(Suppl) 1:S20–S37.
Lim JH, Choi BI. Dysplastic nodules in liver cirrhosis: imaging. Abdom Imaging 2002;27:117–128.
Velazquez RF, Rodriguez M, Navascues CA, Linares A, Perez R, Sotorrios NG, et al. Prospective analysis of risk factors for hepatocellular carcinoma in patients with liver cirrhosis. Hepatology 2003;37:520–527.
Tang H, Oishi N, Kaneko S, Murakami S. Molecular functions and biological roles of hepatitis B virus x protein. Cancer Sci 2006;97:977–983.
Liu J, Lian Z, Han S, Waye MM, Wang H, Wu MC, et al. Downregulation of E-cadherin by hepatitis B virus x antigen in hepatocellullar carcinoma. Oncogene 2006;25:1008–1017.
Tang Y, Chen Y, Ni B, Yang D, Guo S, Wu Y. Up-regulation of the expression of costimulatory molecule CD40 in hepatocytes by hepatitis B virus x antigen. Biochem Biophys Res Commun 2009;384:12–17.
Lian Z, Liu J, Li L, Li X, Clayton M, Wu MC, et al. Enhanced cell survival of Hep3B cells by the hepatitis B x antigen effector, URG11, is associated with upregulation of betacatenin. Hepatology 2006;43:415–424.
Neuveut C, Wei Y, Buendia MA. Mechanisms of HBVrelated hepatocarcinogenesis. J Hepatol 2010;52:594–604.
Vareckova E, Blaskovicova H, Gocnik M, Mikas J, Adamcakova J, Fislova T, et al. Evaluation of clinical specimens for influenza A virus positivity using various diagnostic methods. Acta Virol 2006;50:181–186.
Iavarone M, Lampertico P, Iannuzzi F, Manenti E, Donato MF, Arosio E, et al. Increased expression of vascular endothelial growth factor in small hepatocellular carcinoma. J Viral Hepatol 2007;14:133–139.
Lian ZR, Liu J, Wu MC, Wang HY, Arbuthnot P, Kew M, et al. Hepatitis B x antigen up-regulates vascular endothelial growth factor receptor 3 in hepatocarcinogenesis. Hepatology 2007;45:1390–1399.
Pan JB, Lian ZR, Wallett S, Feitelson MA. The hepatitis B x antigen effector, URG7, blocks tumour necrosis factor alpha-mediated apoptosis by activation of phosphoinositol 3-kinase and beta-catenin. J Gen Virol 2007;88:3275–3285.
Feitelson MA, Lee J. Hepatitis B virus integration, fragile sites, and hepatocarcinogenesis. Cancer Lett 2007;252:157–170.
Liu J, Ahiekpor A, Li L, Li X, Arbuthnot P, Kew M, et al. Increased expression of ErbB-2 in liver is associated with hepatitis B x antigen and shorter survival in patients with liver cancer. Int J Cancer 2009;125:1894–1901.
Chen Y, Zhou Y, Qiu S, Wang K, Liu S, Peng XX, et al. Autoantibodies to tumor-associated antigens combined with abnormal alpha-fetoprotein enhance immunodiagnosis of hepatocellular carcinoma. Cancer Lett 2010;289:32–39.
Diedhiou CJ, Popova OV, Dietz KJ, Golldack D. The SUI-homologous translation initiation factor eIF-1 is involved in regulation of ion homeostasis in rice. Plant Biol (Stuttg) 2008;10:298–309.
Thyagarajan SP, Subramanian S, Thirunalasundari T, Venkateswaran PS, Blumberg BS. Effect of Phyllanthus amarus on chronic carriers of hepatitis B virus. Lancet 1988;2:764–766.
Lin JM, Liu Y, Luo RC. Effect of Scutellaria barbata extract against human hepatocellular Hep-G2 cell proliferation and its mechanism. J South Med Univ (Chin) 2006;26:975–977.
Shim JS, Kim JH, Lee J, Kim SN, Kwon HJ. Antiangiogenic activity of a homoisoflavanone from Cremastra appendiculata. Planta Med 2004;70:171–173.
Xia WB, Xue Z, Li S, Wang SJ, Yang YC, He DX, et al. Chemical constituents from tuber of Cremastra appendiculata. Chin J Chin Mater Med (Chin) 2005;30:1827–1830.
Qi LY, Li HX. The study of chemical composition and pharmacological function on Astragalus L. J Baoding Teach Coll (Chin) 2004;17:40–42.
Liu H, Wei W, Sun WY, Li X. Protective effects of astragaloside IV on porcine-serum-induced hepatic fibrosis in rats and in vitro effects on hepatic stellate cells. J Ethnopharmacol 2009;122:502–508.
Peng BX, Zhou X, Shi JS, Li ZW. Effects of volatile oil and three main components from Curcuma phaeocaulis Valeton on liver cancer and endom etrial carcinoma cell lines. West China J Pharm Sci (Chin) 2007;22:312–331.
Sherman M. Serological surveillance for hepatocellular carcinoma: time to quit. J Hepatol 2010;52:614–615.
Cui X, Wang Y, Kokudo N, Fang D, Tang W. Traditional Chinese medicine and related active compounds against hepatitis B virus infection. Biosci Trends 2010;4:39–47.
Raphael KR, Sabu M, Kumar KH, Kuttan R. Inhibition of N-methyl N′-nitro-N-nitrosoguanidine (MNNG) induced gastric carcinogenesis by Phyllanthus amarus extract. Asian Pac J Cancer Prev 2006;7:299–302.
Liang BZ, Chen LY, Fang YC. Randomized double blind reference drug-controlled clinical trial of a Chinese herbal formula (Phyllanthus Compound) for the treatment of chronic hepatitis B. Chin J Integr Tradit West Med Liver (Chin) 2008;18:196–199.
Zhou DQ, Tong GD, He JS. Effects on HBxAg experessions of nude mice transplanted by human hepatic carcinoma cells of Compound Phyllanthus Urinaria L. Chin J Chin Mater Med (Chin) 2006;31:1649–1651.
Lim LY, Kowdley KV. Chemoprevention of hepatocellular carcinoma in chronic hepatitis B with lamivudine? Gastroenterology 2005;129:2120–21222.
Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004;351:1521–1531.
George VP, Spilios M, Giota T, Georgia V, Maria RG, Irini VZ, et al. Risk of hepatocellular carcinoma (HCC) in chronic hepatitis B (CHB) patients with or without cirrhosis treated with oral antivirals. AASLD 2009;137:S368A.
Liaw YF, Lau GK, Kao JH, Gane E. Hepatitis B e antigen seroconversion: a critical event in chronic hepatitis B virus infection. Dig Dis Sci 2010;55:2727–2734.
Fattovich G, Bortolotti F, Donato F. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol 2008;48:335–352.
0
Views
787
Downloads
12
CSCD
- Meta-XMLDownload
- BibTeXDownload
- EndnoteDownload
- RefMan Download
- NoteExpressDownload
- NoteFirstDownload
Publicity Resources
Related Articles
Related Author
Related Institution
- Address：1 Caochang, xiyuan, Beijing, People's Republic of China Postal code：100091
- Tel：010-62886827, 62877592 Fax：010-62874291
- Technical support is provided by Beijing Founder electronics co., LTD 京ICP备05067934号-1
京公网安备11010802024621 - It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
- Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.
